Clinical Insights in Myelofibrosis: Addressing Unmet Needs & Advancing Outcomes - Episode 3

Challenges With Defining “Ruxolitinib Failure” or Suboptimal Response to Ruxolitinib in MF

,

Panelists discuss how they define “ruxolitinib failure” and a suboptimal response, when they consider switching from first-line ruxolitinib, and how they differentiate between myelofibrosis-induced and JAK-induced cytopenias.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Clinical Perspectives: Firstline Treatment Landscape in Higher-Risk MF
    EP. 2: Tackling Complex Clinical Scenarios: MF Patients With Thrombocytopenia and Anemia
    Now Viewing
    EP. 3: Challenges With Defining “Ruxolitinib Failure” or Suboptimal Response to Ruxolitinib in MF
    EP. 4: Clinical Insights on Managing Ruxolitinib Cytopenias: Patient-Focused Approach
    EP. 5: Practice Takeaways: Treating MF Patients—Key Strategies for Community Providers
    1. Dr Kuykendall to Dr Konala: Switching gears a bit, Dr Konala: How do you define “ruxolitinib failure?” What is a suboptimal response, in your clinical opinion?
    2. Dr Kuykendall: Please comment on your threshold or when you might consider switching from first-line ruxolitinib and how you differentiate myelofibrosis-induced cytopenias (anemia or thrombocytopenia) from JAK-induced cytopenias.
    x